Stock listing
Munich:04X Personalis, Inc. Aktie
German listing (Munich) of Personalis, Inc. · home listing NASDAQ:PSNL
Follow Personalis, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PSNL
$14.27 USD -0.71 (-4.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PSNL
- Day range
- $14.23 – $14.67 USDNov 20, 2026
- Volume
- 3.34M sharesNov 20, 2026
- Market cap
- $1.55B USDAt the close on Nov 20, 2026 · price × 108.4M shares outstanding
- 52-week range
- $4.96 – $18.89 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $44.63M USDMedian day 2.32M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PSNL · Home | $14.27 USD | -0.71 (-4.7%) | 3,335,328 | $14.55 | $14.67 | $14.23 | $14.98 | Close on Nov 20, 2026 |
| Frankfurt:04X | €13.22 EUR | -0.71 (-5.1%) | 190 | €13.07 | €13.22 | €13.07 | €13.93 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PSNL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $14.27 | -0.71 | -4.7% | $14.55 | $14.67 | $14.23 | 3,335,328 | |
| $14.98 | +0.18 | +1.2% | $14.73 | $15.08 | $14.70 | 1,466,535 | |
| $14.80 | 0.00 | 0.0% | $14.81 | $15.02 | $14.52 | 3,134,964 | |
| $14.80 | -0.91 | -5.8% | $15.60 | $15.69 | $14.78 | 6,272,680 | |
| $15.71 | -0.15 | -0.9% | $15.90 | $15.94 | $15.58 | 2,803,799 | |
| $15.86 | -0.10 | -0.6% | $15.90 | $15.95 | $15.81 | 1,864,808 | |
| $15.96 | +0.08 | +0.5% | $15.90 | $16.04 | $15.90 | 1,139,009 | |
| $15.88 | -0.07 | -0.4% | $15.88 | $16.07 | $15.81 | 1,755,224 | |
| $15.95 | +0.16 | +1.0% | $15.80 | $16.00 | $15.80 | 2,323,917 | |
| $15.79 | +0.24 | +1.5% | $15.55 | $15.81 | $15.55 | 3,000,168 | |
| $15.55 | -0.24 | -1.5% | $15.76 | $15.85 | $15.52 | 3,788,256 | |
| $15.79 | +0.04 | +0.3% | $15.85 | $15.91 | $15.69 | 2,217,742 | |
| $15.75 | -0.01 | -0.1% | $15.90 | $15.97 | $15.75 | 2,930,166 | |
| $15.76 | -0.06 | -0.4% | $15.92 | $15.93 | $15.75 | 2,202,758 | |
| $15.82 | -0.105 | -0.7% | $15.84 | $15.91 | $15.65 | 2,364,402 | |
| $15.93 | -0.075 | -0.5% | $15.98 | $16.05 | $15.88 | 749,165 | |
| $16.00 | +0.02 | +0.1% | $15.93 | $16.11 | $15.86 | 1,228,822 | |
| $15.98 | +0.10 | +0.6% | $15.86 | $16.13 | $15.80 | 1,829,253 | |
| $15.88 | +0.03 | +0.2% | $15.81 | $15.99 | $15.77 | 1,140,587 | |
| $15.85 | +0.03 | +0.2% | $15.73 | $15.89 | $15.67 | 1,115,900 | |
| $15.82 | -0.08 | -0.5% | $15.90 | $15.96 | $15.63 | 2,694,800 | |
| $15.90 | -0.04 | -0.3% | $15.76 | $16.12 | $15.76 | 2,791,300 | |
| $15.94 | +0.06 | +0.4% | $15.94 | $16.00 | $15.85 | 2,380,300 | |
| $15.88 | +0.23 | +1.5% | $15.83 | $16.02 | $15.75 | 3,155,600 | |
| $15.65 | -0.28 | -1.8% | $15.86 | $16.00 | $15.51 | 3,305,800 | |
| $15.93 | +0.03 | +0.2% | $15.88 | $16.08 | $15.83 | 2,141,000 | |
| $15.90 | +0.05 | +0.3% | $15.71 | $16.00 | $15.68 | 3,262,400 | |
| $15.85 | +0.05 | +0.3% | $15.82 | $15.97 | $15.79 | 3,817,200 | |
| $15.80 | -0.20 | -1.2% | $16.01 | $16.17 | $15.80 | 2,254,300 | |
| $16.00 | -0.06 | -0.4% | $16.19 | $16.24 | $15.98 | 1,835,900 | |
| $16.06 | +0.06 | +0.4% | $15.92 | $16.20 | $15.92 | 1,467,500 | |
| $16.00 | -0.03 | -0.2% | $15.78 | $16.10 | $15.68 | 3,817,900 | |
| $16.03 | -0.37 | -2.3% | $16.25 | $16.58 | $15.84 | 5,659,800 | |
| $16.40 | +0.12 | +0.7% | $16.12 | $16.47 | $16.02 | 1,702,500 | |
| $16.28 | +0.11 | +0.7% | $16.38 | $16.44 | $16.12 | 1,139,100 | |
| $16.17 | -0.11 | -0.7% | $16.22 | $16.32 | $16.07 | 1,659,800 | |
| $16.28 | -0.07 | -0.4% | $16.42 | $16.59 | $16.26 | 981,400 | |
| $16.35 | +0.03 | +0.2% | $16.25 | $16.47 | $16.08 | 1,037,800 | |
| $16.32 | -0.14 | -0.9% | $16.22 | $16.48 | $16.00 | 1,669,500 | |
| $16.46 | -0.11 | -0.7% | $16.74 | $16.77 | $16.38 | 1,014,000 | |
| $16.57 | +0.22 | +1.3% | $16.16 | $16.63 | $16.10 | 1,705,800 | |
| $16.35 | -0.01 | -0.1% | $16.16 | $16.42 | $16.09 | 1,123,800 | |
| $16.36 | +0.12 | +0.7% | $16.29 | $16.48 | $16.13 | 1,369,300 | |
| $16.24 | -0.16 | -1.0% | $16.38 | $16.50 | $16.07 | 1,816,200 | |
| $16.40 | +0.17 | +1.0% | $16.30 | $16.44 | $16.12 | 3,180,400 | |
| $16.23 | +0.12 | +0.7% | $16.42 | $16.45 | $16.13 | 5,649,400 | |
| $16.11 | +0.01 | +0.1% | $16.20 | $16.39 | $15.96 | 2,255,900 | |
| $16.10 | -0.19 | -1.2% | $16.15 | $16.40 | $15.92 | 2,426,600 | |
| $16.29 | +0.08 | +0.5% | $16.15 | $16.40 | $16.05 | 1,690,100 | |
| $16.21 | -0.12 | -0.7% | $16.46 | $16.58 | $16.19 | 1,407,000 | |
| $16.33 | -0.07 | -0.4% | $16.07 | $16.49 | $16.00 | 2,296,700 | |
| $16.40 | -0.20 | -1.2% | $16.60 | $16.83 | $16.38 | 2,782,900 | |
| $16.60 | -0.60 | -3.5% | $17.20 | $17.35 | $16.46 | 2,548,500 | |
| $17.20 | +0.37 | +2.2% | $16.67 | $17.23 | $16.52 | 2,522,200 | |
| $16.83 | +0.10 | +0.6% | $16.95 | $17.00 | $16.44 | 2,492,800 | |
| $16.73 | -0.33 | -1.9% | $17.14 | $17.16 | $16.71 | 2,225,500 | |
| $17.06 | +0.28 | +1.7% | $17.00 | $17.38 | $16.81 | 3,618,900 | |
| $16.78 | -0.29 | -1.7% | $17.00 | $17.24 | $16.60 | 2,845,900 | |
| $17.07 | +0.27 | +1.6% | $16.75 | $17.24 | $16.60 | 2,973,200 | |
| $16.80 | -0.28 | -1.6% | $17.08 | $17.64 | $16.55 | 4,943,700 | |
| $17.08 | -0.17 | -1.0% | $17.18 | $17.50 | $16.84 | 2,174,600 | |
| $17.25 | +0.19 | +1.1% | $17.09 | $17.48 | $16.80 | 2,897,036 | |
| $17.06 | -1.32 | -7.2% | $17.01 | $17.43 | $16.79 | 4,793,048 | |
| $18.38 | +1.50 | +8.9% | $16.66 | $18.89 | $16.62 | 7,996,300 | |
| $16.88 | +1.07 | +6.8% | $15.91 | $17.06 | $15.91 | 14,208,500 |
- Ticker
- Munich:04X
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Personalis Reports Third Quarter Results
Latest earnings call · May 7, 2026
Personalis (NASDAQ:PSNL) Q1 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Merger or Acquisition (November 2026)
Merger or acquisition · 30 slides
Latest news
Personalis Reports Third Quarter Results
Nov 4, 2026
Closed $15.55 (-1.5%) on Nov 5, 2026
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Oct 21, 2026
Closed $15.90 (-0.3%) on Oct 21, 2026
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Oct 20, 2026
Closed $15.94 (+0.4%) on Oct 20, 2026
Personalis Reports Second Quarter Results and Recent Highlights
Aug 4, 2026
Closed $13.52 (0.0%) on Aug 5, 2026
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Jul 20, 2026
Closed $13.34 (-13.3%) on Jul 20, 2026
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Jul 14, 2026
Closed $15.03 (-0.1%) on Jul 14, 2026
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Jun 9, 2026
Closed $9.75 (-2.9%) on Jun 9, 2026
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Jun 2, 2026
Closed $11.14 (-1.1%) on Jun 2, 2026
Personalis, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 28 in the last 12 months · 221 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest May 7, 2026
- Decks
- 6 decks · latest Nov 12, 2026
Where Personalis, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PSNL · Home listing | NASDAQ | United States | USD |
| Tradegate:04X | Tradegate | Germany | EUR |
| gettex:04X | gettex | Germany | EUR |
| Lang & Schwarz:A2PLTK | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PLTK | LS Exchange | Germany | EUR |
| BOATS:PSNL | BOATS | United States | USD |
| Frankfurt:04X | Frankfurt | Germany | EUR |
| Dusseldorf:04X | Dusseldorf | Germany | EUR |
| Hamburg:04X | Hamburg | Germany | EUR |
| Munich:04X · This page | Munich | Germany | EUR |
| Stuttgart:04X | Stuttgart | Germany | EUR |
| Hanover:04X | Hanover | Germany | EUR |
| Xetra:04X | Xetra | Germany | EUR |
Valuation
EV/sales 17.3× against a median of 4.0×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.39B USD
- P/E
- Loss
- EV/sales
- 17.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.3×
- Gross margin
- 16.7%
- Operating margin
- −156.7%
- Net margin
- −147.7%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 2.03
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Personalis, Inc. · NASDAQ:PSNL | US$1.55B | US$1.39B | n/a | 17.3× | n/a | 7.3× | −147.7% | 0.2× | 2.03 |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| PolyPeptide Group AG · SIX:PPGN | US$1.62B | US$1.71B | n/a | 4.0× | 34.2× | 4.2× | −5.4% | 0.4× | n/a |
| Sino Biological Inc. Class A · SZSE:301047 | US$1.45B | US$1.01B | 54.1× | 8.5× | n/a | 1.9× | 22.6% | 0.0× | n/a |
| Qingdao Haier Biomedical Co., Ltd. Class A · SSE:688139 | US$1.41B | US$1.16B | 34.7× | 3.1× | n/a | 2.1× | 10.8% | 0.0× | n/a |
| Nanjing Vazyme Biotech Co., Ltd. Class A · SSE:688105 | US$1.38B | US$960.3M | 14,463× | 4.1× | n/a | 2.5× | 0.0% | 0.0× | n/a |
| GeneDx Holdings Corp. · NASDAQ:WGS | US$1.36B | US$1.34B | n/a | 2.9× | n/a | 5.6× | −24.1% | 0.6× | 1.73 |
| PharmaBlock Sciences (Nanjing), Inc. Class A · SZSE:300725 | US$1.29B | US$1.08B | 38.9× | 3.3× | n/a | 1.9× | 10.1% | 0.0× | n/a |
| Median of the others | US$1.53B | US$1.41B | 54.2× | 4.0× | 34.2× | 3.8× | 5.1% | 0.0× | 1.70 |
Forecasts
1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.16 · 2 analysts
- Revenue, year to Dec 2026
- 88.65M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Aaron Tachibana | Chief Financial Officer and Chief Operating Officer |
| Richard Chen | President and Chief Medical Officer |
| Stephen Moore | Senior Vice President, Chief Legal Officer |
| Caroline Corner | Investor Relations |
| Ashish Kheterpal | Senior Vice President, Chief Information Officer |
| Christian Haudenschild | Senior Vice President, Genomic Science |
| Deepshikha Bhandari | Senior Vice President, Regulatory, Quality & Clinical Compliance |
| Stephane Mouradian | Senior Vice President, Business Development |
Board
| Director | Role |
|---|---|
| Karin Eastham | Chair |
| A. Blaine Bowman | Director |
| Christopher Hall | Director |
| Kenneth J. Widder | Director |
| Lonnie Shoff | Director |
| Olivia Bloom | Director |
| Woodrow A. Myers | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Personalis (NASDAQ:PSNL) Q1 2026 Earnings Call | Thu, May 07, 2026 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q1 2025 Earnings Call | Tue, May 06, 2025 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q1 2024 Earnings Call | Wed, May 08, 2024 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 5:00 PM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| Personalis (NASDAQ:PSNL) Q1 2023 Earnings Call | Wed, May 03, 2023 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q4 2022 Earnings Call | Thu, Feb 23, 2023 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q3 2022 Earnings Call | Wed, Nov 02, 2022 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q2 2022 Earnings Call | Wed, Aug 03, 2022 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q1 2022 Earnings Call | Wed, May 04, 2022 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q4 2021 Earnings Call | Thu, Feb 24, 2022 · 5:00 PM ET | Replay |
| Personalis (NASDAQ:PSNL) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 8:30 AM ET | Replay |
| Personalis (NASDAQ:PSNL) Q1 2021 Earnings Call | Wed, May 05, 2021 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −1.5% |
| Q2 2026 | Aug 4, 2026 · After close | 0.0% |
| Q1 2026 | May 7, 2026 · After close | −0.2% |
| Q4 2025 | Feb 26, 2026 | +9.0% |
| Q3 2025 | Nov 4, 2025 · After close | −12.3% |
| Q2 2025 | Aug 5, 2025 · After close | −21.9% |
| Q1 2025 | May 6, 2025 · After close | +21.0% |
| Q4 2024 | Feb 26, 2025 · After close | −5.4% |
| Q3 2024 | Nov 6, 2024 · After close | −22.6% |
| Q2 2024 | Aug 7, 2024 · After close | +19.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +5.4% |
| Q4 2023 | Feb 28, 2024 · After close | +6.2% |
| Q3 2023 | Nov 7, 2023 · After close | +21.5% |
| Q2 2023 | Aug 8, 2023 · After close | +0.5% |
| Q1 2023 | May 3, 2023 · After close | −5.0% |
| Q4 2022 | Feb 23, 2023 · After close | −7.2% |
| Q3 2022 | Nov 2, 2022 · After close | 0.0% |
| Q2 2022 | Aug 3, 2022 · After close | +0.5% |
| Q1 2022 | May 4, 2022 · After close | −9.9% |
| Q4 2021 | Feb 24, 2022 · After close | +2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (November 2026) | Merger or acquisition | 30 slides | Nov 12, 2026 |
| Merger or Acquisition (October 2026) | Merger or acquisition | 5 slides | Oct 21, 2026 |
| Investor Presentation (August 2026) | Investor deck | 17 slides | August 2026 |
| Merger or Acquisition (July 2026) | Merger or acquisition | 11 slides | Jul 20, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 20 slides | May 6, 2025 |
| ESMO Congress 2023 | Conference | 15 slides | Oct 21, 2023 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$17.8M raised · US$5.89 a share | May 6, 2025 |
| Strategic investment of common stock Announced: US$50M · US$3.56 a share Buyers: Merck ($50 million of common stock; approximately 14 million shares, approximately 16.5 percent beneficial ownership following closing) | Dec 19, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jun 19, 2019.
- Price
- US$17.00 a share
- Shares offered
- 7,921,500 shares of common stock
- Offering size
- US$134.7 million
- Underwriters' option
- Up to 1,188,225 more shares
- Underwriters
- MORGAN STANLEY, BofA MERRILL LYNCH, COWEN, OPPENHEIMER & CO. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 27, 2019 |
| Filed publicly | May 23, 2019 |
| Amended once | Jun 7, 2019 |
| Shares registered with an exchange | Jun 17, 2019 |
| Declared effective by the SEC | Jun 19, 2019 |
| Final prospectus, with the price | Jun 20, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 20, 2019 |
| EFFECT · Notice that a registration is effective | Jun 19, 2019 |
| S-1MEF · Registration of more shares for the same offering | Jun 19, 2019 |
| CERT · Exchange's certificate of listing | Jun 18, 2019 |
| CORRESP · Letter to the SEC | Jun 17, 2019 |
| CORRESP · Letter to the SEC | Jun 17, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 17, 2019 |
| S-1/A · Registration statement, amended | Jun 7, 2019 |
| CORRESP · Letter to the SEC | Jun 4, 2019 |
| S-1 · Registration statement | May 23, 2019 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | May 10, 2019 |
| DRS/A · Draft registration statement, amended | May 10, 2019 |
| UPLOAD · Letter from the SEC | Apr 23, 2019 |
| DRS · Draft registration statement | Mar 27, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 20, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69.6M | 84.6M | 73.5M | 65.0M | 85.5M | 78.6M | 65.2M | 37.8M | 9.39M |
| Cost of revenue | 53.9M | 57.8M | 55.3M | 51.7M | 53.8M | 58.5M | 43.1M | 26.0M | 11.7M |
| Gross profit | 15.8M | 26.8M | 18.2M | 13.3M | 31.7M | 20.1M | 22.1M | 11.8M | -2.34M |
| Research and development | 50.3M | 48.9M | 64.8M | 64.9M | 49.3M | 28.6M | 22.4M | 14.3M | 9.92M |
| Selling, general and administrative | 53.6M | 46.2M | 49.7M | 64.0M | 47.7M | 33.7M | 22.1M | 11.3M | 9.90M |
| Operating income | -88.1M | -68.3M | -109.9M | -115.5M | -65.4M | -42.1M | -22.4M | -13.8M | -22.2M |
| Depreciation and amortization | 10.0M | 10.9M | 11.3M | 8.43M | 6.01M | 5.76M | 4.75M | 3.07M | 1.22M |
| EBITDA | -78.0M | -57.3M | -98.6M | -107.1M | -59.3M | -36.4M | -17.7M | -10.7M | -20.9M |
| Interest expense | 205.0K | 24.0K | 110.0K | 201.0K | 184.0K | 2.00K | 1.13M | 1.89M | 1.30M |
| Income before tax | -81.2M | -81.3M | -108.2M | -113.3M | -65.2M | -41.2M | -25.1M | -19.9M | -23.6M |
| Income tax | 21.0K | 18.0K | 83.0K | 40.0K | 14.0K | 57.0K | 9.00K | 7.00K | 5.00K |
| Net income | -81.3M | -81.3M | -108.3M | -113.3M | -65.2M | -41.3M | -25.1M | -19.9M | -23.6M |
| Earnings per share, basic | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | -1.39 | -6.49 | -7.78 |
| Earnings per share, diluted | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | -1.39 | -6.49 | -7.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 124.2M | 91.4M | 57.0M | 89.1M | 105.6M | 68.5M | 55.0M | 19.7M | 22.6M |
| Short-term investments | 115.7M | 93.6M | 57.2M | 78.5M | 181.5M | 134.8M | 73.2M | 0 | 0 |
| Receivables | 16.2M | 8.14M | 17.7M | 16.6M | 18.5M | 6.35M | 3.30M | 4.46M | 1.94M |
| Inventory | 6.14M | 3.98M | 5.66M | 6.38M | 4.08M | 2.67M | 1.42M | 2.13M | 822.0K |
| Current assets | 268.0M | 203.0M | 146.7M | 199.7M | 318.2M | 220.7M | 139.6M | 29.6M | 26.7M |
| Property, plant and equipment | 44.8M | 48.3M | 57.4M | 61.9M | 19.6M | 11.8M | 14.1M | 11.5M | 6.34M |
| Goodwill | 0 | 0 | |||||||
| Total assets | 334.2M | 270.3M | 225.1M | 292.7M | 396.5M | 244.8M | 157.3M | 41.7M | 33.6M |
| Accounts payable | 13.0M | 6.40M | 14.9M | 12.9M | 9.22M | 8.30M | 7.34M | 6.57M | 4.04M |
| Current liabilities | 39.6M | 31.1M | 47.2M | 33.1M | 31.3M | 40.6M | 50.0M | 57.9M | 49.0M |
| Long-term debt | 683.0K | 292.0K | |||||||
| Total debt | 39.9M | 44.2M | 47.7M | 48.6M | 58.3M | 0 | 0 | 5.00M | 17.8M |
| Total liabilities | 73.0M | 67.3M | 95.7M | 74.6M | 86.2M | 49.9M | 50.6M | 58.7M | 126.2M |
| Shareholders' equity | 261.2M | 203.0M | 129.4M | 218.1M | 310.3M | 194.9M | 106.7M | -106.4M | -92.6M |
| Shares outstanding | 102.5M | 85.2M | 50.5M | 46.7M | 44.9M | 39.1M | 31.2M | 3.09M | 43.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -74.9M | -45.1M | -56.3M | -70.2M | -70.8M | -42.7M | -18.1M | 5.57M | 290.0K |
| Capital spending | -4.50M | -1.60M | -10.9M | -49.9M | -11.1M | -3.25M | -8.38M | -7.85M | -5.16M |
| Free cash flow | -79.5M | -46.8M | -67.2M | -120.1M | -81.9M | -45.9M | -26.5M | -2.28M | -4.87M |
| Cash from investing | -22.6M | -35.1M | 13.1M | 52.5M | -60.1M | -65.1M | -81.6M | -7.85M | -5.16M |
| Cash from financing | 130.3M | 114.7M | 11.0M | 1.37M | 169.7M | 121.3M | 134.9M | -591.0K | 16.4M |
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 2.46M | 166.4M | 121.3M | 145.4M | 76.0K | 65.0K | |||
| Change in cash | 32.8M | 34.4M | -32.1M | -16.5M | 38.9M | 13.5M | 35.3M | -2.87M | 11.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 425 | Nov 12, 2026 | Other filings | SEC |
| 425 | Nov 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 425 | Nov 3, 2026 | Other filings | SEC |
| 425 | Oct 30, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEFM14A | Oct 21, 2026 | Meeting notice | SEC |
| 425 | Oct 20, 2026 | Other filings | SEC |
| 425 | Oct 20, 2026 | Other filings | SEC |
| SC 13E3/A | Oct 20, 2026 | Other filings | SEC |
| 425 | Oct 6, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| SC 13E3/A | Oct 2, 2026 | Other filings | SEC |
| CT ORDER | Oct 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 425 | Sep 15, 2026 | Other filings | SEC |
| SC 13E3 | Aug 31, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 21, 2026 | Big-stake notice | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 20, 2026 | Material contract | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 20, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4/A · Change in ownership, amended | Jun 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 8-K · Current report | May 20, 2026 | Current report | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 13, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 8, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 2, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 8-K · Current report | Nov 28, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 28, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 21, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 9, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 3, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 6, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| S-3 · Registration statement | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 7, 2025 | Results | SEC |
| 8-K · Current report | Dec 27, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 27, 2024 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Dec 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 19, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 30, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 16, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 26, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jul 3, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 28, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 27, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 8-K · Current report | May 21, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 2, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 2, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
This page holds 200 of 560 filings. Open Filings
Cap table
Built by 6ix from Personalis, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 108,403,814
- Fully diluted
- 108,403,814
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 108,403,814 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 108,403,814 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Karin Eastham Other companies: Veracyte, Inc. (Board Member · Since at least Jun 20, 2016); Nektar Therapeutics (Director · Sep 27, 2018 – Sep 16, 2022 · Past); Geron Corporation (Director · May 17, 2016 – Jan 13, 2023 · Past); Illumina, Inc. (Director · May 17, 2016 – May 28, 2019 · Past) | Chair · Since at least Sep 9, 2019 |
| Aaron Tachibana Other companies: Lumentum Holdings Inc. (CFO · Jul 16, 2015 – Aug 18, 2018 · Past); Asyst Technologies Inc (SR. VP and CFO · May 31, 2007 – Nov 20, 2008 · Past) | Chief Financial Officer and Chief Operating Officer · Since at least Jun 19, 2019 |
| Kenneth J. Widder Other companies: QuidelOrtho Corporation (Director · Since at least May 27, 2022); Evoke Pharma Inc (Director · Since at least Sep 24, 2013) | Director · Since at least Jun 13, 2023 |
| Patrick Balthrop Other companies: MaxCyte, Inc. (Non-Executive Director · Since at least Nov 30, 2022); Oxford Immunotec Global PLC (Director · Jan 29, 2016 – Mar 8, 2021 · Past) | Director · Jun 19, 2019 – May 15, 2020 · Past |
| Christopher Hall Other companies: Veracyte, Inc. (President and COO · Jul 22, 2015 – Jun 3, 2019 · Past) | Director · Since at least Dec 31, 2022 |
| Olivia Bloom Other companies: Geron Corporation (EVP, Chief Financial Officer · Feb 8, 2023 – Aug 15, 2023 · Past) | Director · Since at least May 17, 2022 |
| Woodrow A Myers Jr Other companies: Mallinckrodt Inc (Director · Jun 16, 2022 – Nov 14, 2023 · Past) | Director · Since at least Mar 6, 2021 |
| A. Blaine Bowman | Director · Since at least May 12, 2026 |
| Ashish Kheterpal | Senior Vice President, Chief Information Officer · Since at least Nov 5, 2026 |
| Caroline Corner | Investor Relations · Since at least May 13, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Christian Haudenschild | Senior Vice President, Genomic Science · Since at least Nov 5, 2026 |
| Deepshikha Bhandari | Senior Vice President, Regulatory, Quality & Clinical Compliance · Since at least Nov 5, 2026 |
| Jonathan MacQuitty | Director · Jun 19, 2019 – May 14, 2021 · Past |
| Lonnie Shoff | Director · Since at least May 17, 2024 |
| Richard Chen | President and Chief Medical Officer · Since at least Jun 19, 2019 |
| Stephane Mouradian | Senior Vice President, Business Development · Since at least Nov 5, 2026 |
| Stephen Moore | Senior Vice President, Chief Legal Officer · Since at least Feb 17, 2022 |
| Woodrow A. Myers | Director · Since at least May 14, 2026 |
Log in to ask 6ix AI your own questions about Personalis, Inc.